ישראל - עברית - Ministry of Health

bioavenir ltd, israel - isotretinoin - קפסולות רכות - isotretinoin 10 mg - isotretinoin

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - isotretinoin - קפסולות רכות - isotretinoin 20 mg - isotretinoin

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - isotretinoin - קפסולות רכות - isotretinoin 40 mg - isotretinoin

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - isotretinoin - קפסולות רכות - isotretinoin 5 mg - isotretinoin

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - ambrisentan - טבליות מצופות פילם - ambrisentan 10 mg - ambrisentan

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan

ישראל - עברית - Ministry of Health

bioavenir ltd - alendronic acid as sodium 70 mg - tablets - alendronic acid - alendronate bioavenir is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures) .

ישראל - עברית - Ministry of Health

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

ישראל - עברית - Ministry of Health

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin